Lunate Capital Ltd's Q1 2026 13F: 1 position resized, no new positions or exits
Form 13F-HR for the quarter ended Mar 31, 2026 · filed Apr 16, 2026 · 6 reported positions · accession 0001011438-26-000235
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Reduced | REVOLUTION MEDICINES INC (RVMD) | 66.2% | 44.4% | −21.8 pts | −1.65M sh | −75% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
No changes in the top 10 this quarter
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC (RVMD) | 66.2% | 44.4% | |
| 2 | SAILPOINT INC (SAIL) | 23.0% | 33.0% | |
| 3 | LINEAGE INC (LINE) | 7.9% | 16.3% | |
| 4 | NEUMORA THERAPEUTICS INC. (NMRA) | 1.4% | 3.4% | |
| 5 | NAVAN INC (NAVN) | 1.3% | 2.2% | |
| 6 | REVOLUTION MEDICINES INC (RVMDW) | 0.2% | 0.7% |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).